EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

β2‐Adrenergic Receptor Agonist Clenbuterol Protects Against Acute Ischemia/Reperfusion‐Induced Arrhythmia by Regulation of Akt/ eNOS / NO /Cx43 Signaling Pathway

Jing Fu, Li Liu, Qin Fu, Xiaoman Zeng, Xiaoyan Yang iD

Pharmacology Research & Perspectives · 2025

DOI: 10.1002/prp2.70070 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von Jing Fu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Clenbuterol, Myocardial Reperfusion Injury, Adrenergic beta-2 Receptor Agonists, Arrhythmias, Cardiac. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Hainan Provincial Natural Science Foundation of China, Research Fund of the Central Hospital of Wuhan, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ventricular arrhythmias induced by ischemia/reperfusion injury limits the therapeutic effect of early reperfusion therapy for acute myocardial infarction. This study investigated the protective effects of the β2‐adrenergic receptor (β2‐AR) agonist clenbuterol against ischemia/reperfusion‐induced arrhythmias and the underlying mechanism. Anesthetized rats were subjected to 10‐min left coronary artery occlusion and 10‐min reperfusion in vivo. Langendorff‐perfused mice hearts were exposed to 10‐min global ischemia and 10‐min reperfusion. Arrhythmic events were recorded during early reperfusion. Hearts were collected for measuring nitric oxide (NO) concentration and immunoblotting of Connexin 43 (Cx43), endothelial nitric oxide synthase (eNOS), and protein kinase B (Akt). After the ischemia/reperfusion injury in anesthesia rats, clenbuterol markedly reduced the duration and incidence of ventricular tachycardia and ventricular fibrillation, and arrhythmia score, which was abrogated by selective β2‐AR antagonist or Cx43 inhibitor. Furthermore, a marked increase in dephosphorylated Cx43 expression and a decrease in the ratio of phosphorylated Cx43 to total Cx43 were observed after the ischemia/reperfusion injury. Mechanistically, clenbuterol increased the phosphorylation of e‐NOS and NO concentration, while L‐NAME abolished Cx43 phosphorylation and the protective effect of clenbuterol. Clenbuterol also promoted Akt phosphorylation, and blockade of Akt inhibited eNOS phosphorylation and NO production, as well as Cx43 phosphorylation and protective effect of clenbuterol. The present study elucidates that β2‐AR stimulation activates the Akt/eNOS signaling pathway, augments NO bioavailability, maintains Cx43 phosphorylation, and prevents Cx43 remodeling, ultimately attenuating arrhythmia induced by ischemia/reperfusion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClenbuterolMyocardial Reperfusion InjuryAdrenergic beta-2 Receptor AgonistsArrhythmias, CardiacAnimalsNitric Oxide Synthase Type IIIProto-Oncogene Proteins c-aktMaleConnexin 43Signal TransductionNitric OxideRatsMiceRats, Sprague-DawleyVentricular Fibrillation

Stichwörter der Autor:innen

Cx43arrhythmiaclenbuterolischemia–reperfusionβ2 adrenergic receptor agonist

Substanzen

ClenbuterolNitric Oxide Synthase Type IIIProto-Oncogene Proteins c-aktConnexin 43Nitric OxideAdrenergic beta-2 Receptor AgonistsGja1 protein, rat

Autor:innen und Institutionen

  • Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Pharmacy, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Office of Academic Research, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • The Key Laboratory for Drug Target Researches and Pharmacodynamic Evaluation of Hubei Province, Wuhan, China.
  • Division of Cardiology, Wenchang People's Hospital, Wenchang, China.

ORCID-Profile: Xiaoyan Yang

Förderung

  • Hainan Provincial Natural Science Foundation of China
  • Research Fund of the Central Hospital of Wuhan
  • National Natural Science Foundation of China

Zitieren

APA

Fu, J., Liu, L., Fu, Q., Zeng, X., & Yang, X. (2025). β2‐Adrenergic Receptor Agonist Clenbuterol Protects Against Acute Ischemia/Reperfusion‐Induced Arrhythmia by Regulation of Akt/ eNOS / NO /Cx43 Signaling Pathway. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70070

Vancouver

Fu J, Liu L, Fu Q, Zeng X, Yang X. β2‐Adrenergic Receptor Agonist Clenbuterol Protects Against Acute Ischemia/Reperfusion‐Induced Arrhythmia by Regulation of Akt/ eNOS / NO /Cx43 Signaling Pathway. Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70070

BibTeX
@article{Fu2025,
  author = {Fu, Jing and Liu, Li and Fu, Qin and Zeng, Xiaoman and Yang, Xiaoyan},
  title = {β2‐Adrenergic Receptor Agonist Clenbuterol Protects Against Acute Ischemia/Reperfusion‐Induced Arrhythmia by Regulation of Akt/ eNOS / NO /Cx43 Signaling Pathway},
  journal = {Pharmacology Research & Perspectives},
  year = {2025},
  doi = {10.1002/prp2.70070}
}
Kostenlos starten →